Crossmark

Advances in the Pathophysiology and Management of Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension

Published Online: 2022-03-01

Published Print: 2022-03

Authors

Park, Jin-Woo

Okamoto, Luis E.

Biaggioni, Italo https://orcid.org/0000-0001-7667-7083
Funding

Funding for this research was provided by:

national institutes of health (HL144568)

national institutes of health (HL149386)

national institutes of health (NS065736)

national institutes of health (HL122847)

national institutes of health (TR002243)
License Information

Text and Data Mining valid from 2022-03-01

Version of Record valid from 2022-03-01
More Information

Article History

Accepted: 15 November 2021

First Online: 1 March 2022

Declarations

:

: Not applicable.

: Not applicable.

: Not applicable.

: Italo Biaggioni has received consultant fees and research support from Lundbeck and Theravance Biopharma, Inc for the development of therapies for orthostatic hypotension. Italo Biaggioni and Luis Okamoto are patent holders for the use of an automated binder in the treatment of orthostatic hypotension. Jin-Woo Park declares no conflict of interest.

Document is current